Company intelligence / Profile preview
Macrophage Therapeutics
Not specified, New Jersey, United Statesmacrophagetx.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
The company is developing targeted anti-inflammatory and immuno-oncology therapeutics. Their MT-2000 class is designed to convert pro-inflammatory M1 macrophages to anti-inflammatory M2 macrophages, while their MT-1000 class targets and kills Tumor Associated Macrophages (TAMs)[1][2].
- Therapeutic areas
- GastroenterologyCardiovascularImmunologyOncologyInfectious Diseases
- Modalities
- Small molecule drugsBiological products
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Macrophage Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Macrophage Therapeutics.